Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

Immunotherapy Drugs Market by Drug Type (Checkpoint Inhibitors, Interferons, Interleukins, Monoclonal Antibodies, Vaccines, Others), Disease Type (Autoimmune and Inflammatory Diseases, Cancer, Infectious Diseases, Others) and Forecast 2024-2031

$3,000.00

Report Specifications: Market Size, Market Share, Growth Trends, Forecast, Geography

Immunotherapy drugs boosts the body’s natural defenses to fight various diseases. It uses substances made by the body or in a laboratory to improve or restore immune system function. Immunotherapy may work either by stopping or slowing the growth of diseased cells, stopping disease from spreading to other parts of the body, or helping the immune system work better at destroying affected cells. Immune checkpoint inhibitors are drugs, often made of antibodies that unleash an immune system attack on cancer cells. Three checkpoint inhibitors have received rapid approval from the U.S. Food and Drug Administration for cancer, including ipilimumab (Yervoy), pembrolizumab (Keytruda), and nivolumab (Opdivo). Cell-based immunotherapies are effective for some cancers. Therapies such as granulocyte colony-stimulating factor (G-CSF), interferons, imiquimod and cellular membrane fractions from bacteria are licensed for medical use. By targeting surface antigens expressed on tumor cells, monoclonal antibodies have demonstrated efficacy as cancer therapeutics. Antimicrobial immunotherapy, which includes vaccination, involves activating the immune system to respond to an infectious agent.

The global immunotherapy drugs market segmentation is based on drug type (checkpoint inhibitors, interferons, interleukins, monoclonal antibodies, vaccines, others), and disease type (autoimmune and inflammatory diseases, cancer, infectious diseases, others).

The global immunotherapy drugs market report provides market size ($Million 2021 to 2031), market share, trends and forecast (CAGR%, 2024 to 2031). The global immunotherapy drugs market research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World. The global immunotherapy drugs market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.

Major players operating in the global immunotherapy drugs market and profiled in this report include Amgen Inc., F. Hoffmann-La Roche AG, Glaxosmithkline Plc, Johnson & Johnson, Merck & Co., Inc., and Novartis International AG.

DATA INCLUDED: Immunotherapy Drugs Market Size, Immunotherapy Drugs Market Share, Immunotherapy Drugs Market Growth Rates, Immunotherapy Drugs Market Trends, and Immunotherapy Drugs Market Forecast to 2031

Market Data:

  • Base year for estimation: 2023
  • Actual estimates/Historical data: 2021-2031
  • Forecast period: 2024-2031
  • Market representation: Revenue in $million and CAGR % from 2024 to 2031
  • Regional scope: North America, Europe, Asia Pacific, Latin America, Rest of the World (Middle East & Africa)
  • Country scope: U.S., Canada, U.K., Germany, France, Italy, Spain, Japan, China, India, South Korea, Brazil, Mexico, South Africa, South Korea, Saudi Arabia, UAE and others.
  • Report coverage: Revenue forecast, company share, competitive landscape, growth factors, and trends
  • 15% free customization scope: Any specific or custom requirements, which is not currently within the scope of the report, will be provided as a part of customization.

Qualitative Analysis:

  • Industry overview
  • Industry trends
  • Market drivers and restraints
  • Key market opportunities
  • Market size
  • Growth trends
  • Porter’s five forces analysis
  • Market attractiveness analysis
  • Competitive landscape
    • Company overview
    • Financial performance
    • Product portfolio
    • Strategic insights
    • Recent developments

Quantitative Analysis:

  • Market size estimates and forecast for all segments
  • Regional market size estimated and forecast for major countries
  • Company financial performance
  • Competitive landscape: Company market share analysis

Please contact us for offers on individual or multiple report purchases.

  1. Introduction
  2. Executive Summary
    • Market Size Estimation ($million, 2021-2031)
    • Forecast Estimation ($million and CAGR%, 2024-2031)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2031)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Key Questions Answered:
1. What are the factors driving and limiting this market, key success factors and challenges?
2. Which are the leading competitors in the market, their market share, profitability and key trends by product, technology, services portfolio?
3. How do markets perform between countries and regions?
4. What market segments are contributing to maximum share and greatest growth?
5. What are the product or procedure volumes by country and regions?

Actionable Insights Included:
1. Product portfolio matrix (Share vs. Growth)
2. Market attractiveness (Region vs. Growth)
3. Spot matrix (Product vs. Region)
4. Geographic distribution matrix (Share vs. Growth)

Immunotherapy Drugs Market

1. Drug Type
1.1. Checkpoint Inhibitors
1.2. Interferons
1.3. Interleukins
1.4. Monoclonal Antibodies
1.5. Vaccines
1.6. Others

2. Disease Type
2.1. Autoimmune and Inflammatory Diseases
2.2. Cancer
2.3. Infectious Diseases
2.4. Others

3. Geography (Region, Country)
3.1. North America (U.S., Canada)
3.2. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.3. Latin America (Brazil, Mexico, Rest of LA)
3.4. Asia Pacific (Japan, China, India, Rest of APAC)
3.5. Rest of the World (Middle East & Africa)

4. Company Profiles
4.1. Amgen Inc.
4.2. F. Hoffmann-La Roche AG
4.3. Glaxosmithkline Plc
4.4. Johnson & Johnson
4.5. Merck & Co., Inc.
4.6. Novartis International AG

    Request ToC / Sample Report

    Full Name*

    Company Email*

    Phone Number* [Please add country code]

    Subject*

    Message*

    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com